## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the instant application:

1. (Currently amended) ~~A~~ An antisense compound ~~8 to 50~~ 15 to 25 nucleobases in length targeted to a nucleic acid molecule encoding human stearoyl-CoA desaturase, wherein the antisense compound specifically hybridizes with a sequence within the range of nucleotides 2989 to 3054 of SEQ ID NO: 3 with at least 90% complementarity ~~a nucleic acid molecule encoding human stearoyl-CoA desaturase~~ and inhibits the expression of human stearoyl-CoA desaturase.

2. (Currently amended) The antisense compound according to claim 1, which is an antisense oligonucleotide.

3. (Canceled)

4. (Currently amended) The antisense compound according to claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (Currently amended) The antisense compound according to claim 4, wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (Currently amended) The antisense compound according to claim 2, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (Currently amended) The antisense compound according to claim 6, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (Currently amended) The antisense compound according to claim 2, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (Currently amended) The antisense compound according to claim 8, wherein the modified nucleobase is a 5-methylcytosine.

10. (Currently amended) The antisense compound according to claim 2, wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (Currently amended) The antisense compound according to claim 2, wherein said antisense oligonucleotide inhibits expression of said human stearoyl CoA desaturase by at least 10% in a suitable assay.

12-20 (Canceled)

21. (Currently amended) A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

22-23 (Canceled)

24. (Withdrawn) A method of inhibiting the expression of human stearoyl-CoA desaturase in cells or tissues comprising contacting the cells or tissues with the compound of claim 1 so that expression of human stearoyl-CoA desaturase is inhibited.

25. (Withdrawn) A method of treating a human having a disease or condition associated with human stearoyl-CoA desaturase comprising administering to the human a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of human stearoyl-CoA desaturase is inhibited.

26. (Withdrawn) The method according to claim 25, wherein the condition involves abnormal lipid metabolism.

27. (Withdrawn) The method according to claim 25, wherein the condition involves abnormal cholesterol metabolism.

28. (Withdrawn) The method according to claim 25, wherein the condition is atherosclerosis.

29. (Withdrawn) The method according to claim 25, wherein the disease is cardiovascular disease.

30. (Canceled)

31. (Withdrawn) A method for improving liver function in an animal having elevated liver enzymes comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of stearoyl CoA desaturase is inhibited and thereby lowers liver enzyme levels.

32. (Withdrawn) A method for treating an obese animal comprising

administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of stearoyl CoA desaturase is inhibited, thereby reducing said animal's weight and appetite.

33. (Canceled)

34. (Withdrawn) A method for treating hepatic fatty degeneration in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense oligonucleotide of claim 1 so that expression of stearoyl CoA desaturase is inhibited, thereby reducing hepatic fatty degeneration.

35. (Withdrawn) The method of claim 25, wherein the condition is non-insulin dependent diabetes mellitus.

36. (Currently amended) The antisense compound according to claim 1, wherein said compound comprises the nucleotide sequence of SEQ ID NO: 29, 30, 124, or 125.

37. (Withdrawn) The method of claim 25, wherein said compound comprises SEQ ID NO: 30.

38. (New) The antisense compound according to claim 1, wherein said compound consists of the nucleotide sequence of SEQ ID NO: 29, 30, 124, or 125.

## SUMMARY OF INTERVIEW

Identification of Claims Discussed

Claims 1 and 12 were discussed.

Identification of Prior Art Discussed

No prior art was discussed.

Results of Interview

The interview included a discussion of possible amendments to Claim 1. Applicants' representatives proposed amending Claim 1 to insert a range of nucleotides of SEQ ID NO: 3. Examiners Schultz and Vivlemore indicated that the inserted range would be examined and searched. The written description rejection of Claim 12 set forth by the Examiner in the Office Action mailed December 12, 2005, was also discussed.